BioXcel Therapeutics (BTAI) Depreciation & Amortization (CF) (2017 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Depreciation & Amortization (CF) of $58000.0 for Q1 2026, down 23.68% year-over-year from $76000.0 in Q1 2025, and down 21.62% quarter-over-quarter from $74000.0 in Q4 2025.
BioXcel Therapeutics (BTAI) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $58000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 23.68% year-over-year to $58000.0; the TTM figure through Mar 2026 stood at $282000.0 (down 8.14% YoY), while the FY2025 annual figure was $300000.0, down 2.91% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $58000.0, down from $74000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $85000.0 in Q3 2022, with the low at $58000.0 in Q1 2026.
- The 5-year median for Depreciation & Amortization (CF) is $77000.0 (2022), against an average of $77176.5.
- The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) grew 18.46% in 2022, then retreated 23.68% in 2026.
- BioXcel Therapeutics' Depreciation & Amortization (CF) stood at $81000.0 in 2022, then declined by 3.7% to $78000.0 in 2023, then fell by 1.28% to $77000.0 in 2024, then decreased by 3.9% to $74000.0 in 2025, then fell by 21.62% to $58000.0 in 2026.
- Business Quant data shows BTAI's Depreciation & Amortization (CF) at $58000.0 in Q1 2026, $74000.0 in Q4 2025, and $75000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.46 Mn | 24.46 Mn | 160,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18,000.00 |
| Jun 30, 2026 | 18,000.00 |
| Mar 31, 2026 | 58,000.00 |
| Mar 31, 2026 | 58,000.00 |
| Dec 31, 2025 | 74,000.00 |
| Dec 31, 2025 | 74,000.00 |
| Sep 30, 2025 | 75,000.00 |
| Sep 30, 2025 | 75,000.00 |
| Jun 30, 2025 | 75,000.00 |
| Jun 30, 2025 | 75,000.00 |
| Mar 31, 2025 | 76,000.00 |
| Mar 31, 2025 | 76,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Sep 30, 2024 | 77,000.00 |
| Sep 30, 2024 | 77,000.00 |
| Jun 30, 2024 | 77,000.00 |
| Jun 30, 2024 | 77,000.00 |
| Mar 31, 2024 | 78,000.00 |
| Mar 31, 2024 | 78,000.00 |